Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL985701 | 0.89 | TSHR (0.70) | TPMTTSHRAPOBEC3AHTTAPOBEC3G | |
| SCHEMBL1302996 | 0.84 | TPMT (0.45) | TPMTTSHRAPOBEC3AHTTAPOBEC3G | |
| SCHEMBL3546802 | 0.81 | TPMT (0.79) | TPMTTSHRAPOBEC3AHTTAPOBEC3G | |
| SCHEMBL18289199 | 0.80 | TPMT (0.40) | TPMTTSHRAPOBEC3AHTTAPOBEC3G | |
| SCHEMBL7655117 | 0.79 | TPMT (0.55) | TPMTTSHRAPOBEC3AHTTAPOBEC3G | |
| SCHEMBL3349066 | 0.79 | TPMT (0.59) | TPMTTSHRAPOBEC3AHTTAPOBEC3G | |
| SCHEMBL9258995 | 0.79 | CA2 (0.48) | TPMTTSHRAPOBEC3AHTTAPOBEC3G | |
| SCHEMBL10672750 | 0.79 | TPMT (0.55) | TPMTTSHRAPOBEC3AHTTAPOBEC3G | |
| SCHEMBL985523 | 0.77 | ALDH1A1 (0.61) | TPMTHTTHPGDHSD17B10ALDH1A1 | |
| SCHEMBL4311603 | 0.77 | TPMT (0.39) | TPMTTSHRAPOBEC3AHTTAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070923-A1 | METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION CONTAINING SAME COMPOUND, AND HYDRATE OF SAME COMPOUND | JW PHARMACEUTICAL CORP (KR) | 2026-03-12 | — | — | US | disclosed |
| US-12497410-B2 | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | JW PHARMACEUTICAL CORPORATION (KR) | 2025-12-16 | — | — | US | disclosed |
| CN-119143779-A | Process for preparing heterocyclic derivative compounds, compositions containing the compounds and hydrates of the compounds | JW 制药公司 | 2024-12-17 | — | — | CN | disclosed |
| EP-3909956-B1 | HYDROCHLORIDE SALT 1.5 HYDRATE OF AN HETEROCYCLIC DERIVATIVE COMPOUND | JW PHARMACEUTICAL CORP (KR) | 2024-12-04 | — | — | EP | disclosed |
| US-12103938-B2 | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | JW PHARMACEUTICAL CORPORATION (KR) | 2024-10-01 | — | — | US | disclosed |
| US-RE50083-E1 | URAT1 inhibitor and use thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2024-08-20 | — | — | US | disclosed |
| CN-114085235-B | Process for preparing heterocyclic derivative compounds, compositions containing the compounds and hydrates of the compounds | JW 制药公司 | 2024-08-13 | — | — | CN | disclosed |
| US-12030895-B2 | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | JW PHARMACEUTICAL CORPORATION (KR) | 2024-07-09 | — | — | US | disclosed |
| US-20240083911-A1 | Method For Preparing Heterocyclic Derivative Compound, Composition Containing Same Compound, And Hydrate of Same Compound | JW PHARMACEUTICAL CORPORATION (KR) | 2024-03-14 | — | — | US | disclosed |
| CN-114127078-B | Heterocompounds and methods of use thereof | 重庆复创医药研究有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-9365508-B2 | Aroyl thiourea derivatives | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2016-06-14 | — | — | US | disclosed |
| EP-2266989-B1 | HETEROCYCLIC DERIVATIVES | C & C RES LAB (KR) | 2015-09-02 | — | — | EP | disclosed |
| EP-2440522-B1 | AROYLTHIOUREA AND ARYLTHIOCARBONYLUREA DERIVATIVES | UNIV DUNDEE (GB) | 2014-11-12 | — | — | EP | disclosed |
| US-8394792-B2 | Heterocyclic derivatives | C&C RESEARCH LABORATORIES (KR) | 2013-03-12 | — | — | US | disclosed |
| US-20120149778-A1 | COMPOUNDS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE | 2012-06-14 | — | — | US | disclosed |
| EP-2440522-A2 | AROYLTHIOUREA AND ARYLTHIOCARBONYLUREA DERIVATIVES | University Court of The University of Dundee (GB) | 2012-04-18 | — | — | EP | disclosed |
| US-20110028467-A1 | HETEROCYCLIC DERIVATIVES | C&C RESEARCH LABORATORIES (KR) | 2011-02-03 | — | — | US | disclosed |
| US-7875631-B2 | e.g.1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline; to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of insulin-like growth factor-1 receptor is observed | ANALYTECON S.A. (CH) | 2011-01-25 | — | — | US | disclosed |
| EP-2266989-A2 | HETEROCYCLIC DERIVATIVES | C&c Research Laboratories (KR) | 2010-12-29 | — | — | EP | disclosed |
| WO-2010142956-A2 | COMPOUNDS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028467-A1 | HETEROCYCLIC DERIVATIVES | XDH, NUDT1, UGDH | TPMT 20/4885TSHR 2646/4885APOBEC3A 2756/4885 |
| US-20240083911-A1 | Method For Preparing Heterocyclic Derivative Compound, Composition Containing Same Compound, And Hydrate of Same Compound | REN, NOD1, NLRP3 | TPMT 187/4885TSHR 3151/4885APOBEC3A 4089/4885 |
| US-12103938-B2 | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | REN, NOD1, NLRP3 | TPMT 187/4885TSHR 3151/4885APOBEC3A 4089/4885 |
| US-20120149778-A1 | COMPOUNDS | AR, NR5A1, NAT1 | TPMT 3302/4885TSHR 319/4885APOBEC3A 4457/4885 |
| US-20260070923-A1 | METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION CONTAINING SAME COMPOUND, AND HYDRATE OF SAME COMPOUND | SLC26A3, SLC10A6, SLC14A1 | TPMT 120/4885TSHR 2678/4885APOBEC3A 4401/4885 |
| US-12497410-B2 | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | REN, NOD1, NLRP3 | TPMT 187/4885TSHR 3151/4885APOBEC3A 4089/4885 |
| US-12030895-B2 | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | REN, NOD1, NLRP3 | TPMT 187/4885TSHR 3151/4885APOBEC3A 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.